Our Benefactors:

The vision of the AICF is to share the burden of patient care of highly specialised diseases where access to innovative care is a challenge. Success for the AICF is to be able to provide uninterrupted treatments based on clinical evidence across specialised diseases.

Those organisations who have provided donations to and partnered with the AICF, previously known as the ICCF include:




Abbvie

Accord Oncology

Cipla Medpro
Janssen Pharmaceutica (Pty) Ltd

Litha Pharma

Netcare


Novartis, South Africa (Pty) Ltd
Novo Nordisk


Roche Products Pty Ltd.
Zebra Medical



Success for the AICF means that patients who have highly specialised diseases receive uninterrupted treatments selected on clinical evidence.